BioTime Inc (BTX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7122
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioTime Inc (BioTime) is a clinical-stage biotechnology company. It focuses on developing cures or treatments based on its core proprietary technology platforms for cell replacement and cell/drug delivery.The company’s aesthetics products under development include Renevia , a potential treatment for facial lipoatrophy and facial aesthetics; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); product for retinal restoration; HyStem for stroke recovery; ReGlyde for viscosupplementation and drug delivery; and bone grafting products. BioTime’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. It also has interests in companies involved in offering therapeutic products in oncology and neurology, and biopsy tests for diagnosis of cancer. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
BioTime Inc, Medical Equipment, Deal Details 12
Partnerships 12
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
Equity Offering 18
OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18
OncoCyte Raises USD10 Million in Private Placement of Shares 19
BioTime Completes Public Offering of Shares for USD28.8 Million 20
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24
BioTime to Raise up to USD25 Million in Private Placement of Shares 26
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27
OncoCyte Raises USD3.2 Million in Private Placement of Units 28
OncoCyte Raises USD7.3 Million in Private Placement of Units 29
BioTime Raises USD5 Million in Private Placement of Shares 30
BioTime Raises USD20.4 Million in Private Placement of Shares 31
OncoCyte Raises USD3.3 Million in Private Placement of Shares 33
BioTime Completes Private Placement Of Shares For US$6.4 Million 34
BioTime Announces Public Offering Of Shares For Up To US$15 Million 35
BioTime Completes Public Offering Of Shares For US$3.5 Million 36
BioTime Completes Private Placement Of Units For US$9 Million 37
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 38
BioTime Announces Private Placement Of Common Stock 40
Acquisition 41
BioIVT Acquires Ascendance Biotech 41
BioTime Inc – Key Competitors 42
BioTime Inc – Key Employees 43
BioTime Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 45
Recent Developments 46
Financial Announcements 46
Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 46
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 48
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 50
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 52
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 54
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 56
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 58
Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 61
Corporate Communications 62
Sep 18, 2018: BioTime appoints Brian Culley as chief executive officer 62
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 63
Feb 26, 2018: BioTime Appoints Gary S. Hogge As Sr. Vice President, Clinical and Medical Affairs 64
Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 65
Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 66
Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 67
Product News 68
Aug 16, 2018: BioTime to present data at the Military Health System Research Symposium 68
May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 69
Other Significant Developments 70
Jan 22, 2018: BioTime Announces 2018 Clinical and Corporate Milestone Targets 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
BioTime Inc, Medical Equipment, Key Facts, 2017 2
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Deals By Market, 2012 to YTD 2018 9
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18
OncoCyte Raises USD10 Million in Private Placement of Shares 19
BioTime Completes Public Offering of Shares for USD28.8 Million 20
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24
BioTime to Raise up to USD25 Million in Private Placement of Shares 26
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27
OncoCyte Raises USD3.2 Million in Private Placement of Units 28
OncoCyte Raises USD7.3 Million in Private Placement of Units 29
BioTime Raises USD5 Million in Private Placement of Shares 30
BioTime Raises USD20.4 Million in Private Placement of Shares 31
OncoCyte Raises USD3.3 Million in Private Placement of Shares 33
BioTime Completes Private Placement Of Shares For US$6.4 Million 34
BioTime Announces Public Offering Of Shares For Up To US$15 Million 35
BioTime Completes Public Offering Of Shares For US$3.5 Million 36
BioTime Completes Private Placement Of Units For US$9 Million 37
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 38
BioTime Announces Private Placement Of Common Stock 40
BioIVT Acquires Ascendance Biotech 41
BioTime Inc, Key Competitors 42
BioTime Inc, Key Employees 43
BioTime Inc, Subsidiaries 44
BioTime Inc, Joint Venture 45

List of Figures
BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[BioTime Inc (BTX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Steris Plc (STE):企業の財務・戦略的SWOT分析
    Steris Plc (STE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CYBG PLC:企業の戦略・SWOT・財務情報
    CYBG PLC - Strategy, SWOT and Corporate Finance Report Summary CYBG PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Vexim SA (ALVXM):企業の財務・戦略的SWOT分析
    Summary Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controll …
  • Evertec Inc (EVTC):企業の財務・戦略的SWOT分析
    Summary Evertec Inc (Evertec) is a technology and communication company that offers transaction processing services. The company’s services include payment processing, merchant acquiring and business process management. Its payment processing services comprise card issuing and acquiring processing; …
  • Cancer Genetics Inc (CGIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic info …
  • Eagle Insurance Ltd:企業の戦略・SWOT・財務分析
    Eagle Insurance Ltd - Strategy, SWOT and Corporate Finance Report Summary Eagle Insurance Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Integra LifeSciences Holdings Corporation:企業の戦略・SWOT・財務情報
    Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Cynosure Inc (CYNO)-医療機器分野:企業M&A・提携分析
    Summary Cynosure Inc (Cynosure) develops, manufactures and markets aesthetic and medical treatment systems. The company’s light-based aesthetic treatment systems are used in the treatment of skin revitalization and scar reduction, hair removal, gynecology, pigmentation, tattoo removal, wrinkle reduc …
  • Teladoc Health Inc (TDOC):医療機器:M&Aディール及び事業提携情報
    Summary TelaDoc Health Inc (Teladoc Health) is a provider of telehealth services. The company offers short term prescription for amoxicillin, azithromycin, bactrim DS, augmentin, cipro, tessalon perles, flonase nasal spray, pyridium, prednisone and diflucan. It provides telehealth services for cold …
  • Eni SpA (ENI)-エネルギー分野:企業M&A・提携分析
    Summary Eni S.p.A. (Eni) is an integrated oil and gas company, which carries out oil and natural gas exploration, field development and production activities. It also involves in supply, trading and shipping of natural gas, LNG, electricity and fuels. The company manages developed and undeveloped ac …
  • Vstecs Holdings Ltd
    Vstecs Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Vstecs Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Indena SpA:企業の戦略的SWOT分析
    Indena SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Bank of Ireland:戦略・SWOT・企業財務分析
    Bank of Ireland - Strategy, SWOT and Corporate Finance Report Summary Bank of Ireland - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Imagination Technologies Group plc:企業のM&A・事業提携・投資動向
    Imagination Technologies Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Imagination Technologies Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • Sandvik AB:企業の戦略・SWOT・財務分析
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Veritone, Inc. (VERI):企業の財務・戦略的SWOT分析
    Veritone, Inc. (VERI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • AcelRx Pharmaceuticals Inc (ACRX):企業の財務・戦略的SWOT分析
    AcelRx Pharmaceuticals Inc (ACRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Samchully Co Ltd (004690):企業の財務・戦略的SWOT分析
    Samchully Co Ltd (004690) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tampa Electric Co:電力:M&Aディール及び事業提携情報
    Summary Tampa Electric Company (TEC), a subsidiary of Emera Inc., is an energy utility. It conducts the generation, purchase, transmission, distribution and sale of electricity and the distribution, purchase and sale of natural gas in Florida. The service area for electric operations covers West Cen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆